TCM
CORT icon

Timpani Capital Management’s Corcept Therapeutics CORT Stock Holding History

Timpani Capital Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-80,568
Closed -$1.27M – 105
2018
Q2 		$1.27M Sell
80,568
-164,711
-67% -$2.87M 0.37% 80
2018
Q1 		$4.04M Buy
245,279
+82,685
+51% +$1.53M 1.41% 25
2017
Q4 		$2.94M Sell
162,594
-11,117
-6% -$201K 1.06% 41
2017
Q3 		$3.35M Buy
173,711
+47,923
+38% +$715K 1.22% 26
2017
Q2 		$1.48M Buy
+125,788
New +$1.37M 0.55% 75

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Timpani Capital Management's CORT Position: Q3 2018 in Review

Timpani Capital Management sold out of Corcept Therapeutics (CORT) in Q3 2018, closing a stake of 80,568 shares — an estimated $1.27M sold.

Timpani Capital Management first reported a position in CORT in Q2 2017 and held it in 5 quarters. The position peaked at $4.04M in Q1 2018. 207 funds tracked by Wall St. Rank hold CORT as of Q3 2018.

  • Timpani Capital Management reported no remaining Corcept Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Timpani Capital Management sold 80,568 Corcept Therapeutics shares in Q3 2018, an estimated $1.27M.
  • Timpani Capital Management first reported a position in Corcept Therapeutics in Q2 2017 and held it in 5 quarters.
  • Timpani Capital Management's Corcept Therapeutics position peaked at $4.04M in Q1 2018.
  • 207 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2018.

Based on Timpani Capital Management's 13F filing for Q3 2018, filed 13 Nov 2018.